Market Overview:
The global dabigatran and dabigatran generic drugs market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of thromboembolic disorders, rising geriatric population, and technological advancements in the field of drug discovery. Based on type, the global dabigatran and dabigatran generic drugs market is segmented into 75 mg, 110 mg, 150 mg. Among these segments, the 110 mg segment is expected to account for a major share of the global market during the forecast period. This can be attributed to its higher efficacy as compared to other dosage forms available in the market. Based on application,the global dabigatran and dabigatan generic drugsmarket is segmented into online salesand offline sales channels.
Product Definition:
Dabigatran is a medication used to prevent blood clots. It is taken by mouth. Dabigatran generic drugs are medications that have the same active ingredients as the brand name drug, but are sold under a different name. The importance of dabigatran and dabigatran generic drugs lies in their ability to provide an affordable alternative to the brand-name product while maintaining equivalent quality and effectiveness.
75 mg:
75 mg is used for the treatment of acute coronary syndrome (ACS) and unstable angina pectoris. ACS is a medical condition, which occurs when there is an increase in blood pressure, heart rate, and oxygen demand by the body.
110 mg:
Dabigatran is a new oral anticoagulant drug developed to prevent the formation of blood clots. The active ingredient in Dabigatran, called as direct thrombin inhibitor (DTI), works by decreasing the ability of blood coagulation factor II (F2) to form blood clots.
Application Insights:
The online sales segment held the largest share of around 60.0% in 2017. The growth is attributed to factors such as high adoption of e-commerce for purchasing medicine and convenience among various customers worldwide. Furthermore, growing penetration of online pharmacies coupled with rising awareness about generic drugs is further expected to drive the global dabigatran & dabigatran generic drugs market over the forecast period.
Offline sales accounted for a significant share in 2017 owing to presence of major pharmaceutical companies that manufacture these medicines and due to distribution channels being limited only within specific geographical regions, such as North America and Europe; therefore, limiting its reach globally.
Dabigatran & dabigatran are available both generically as well as under different brand names including Pradaxa®, Xarelto®, Zomacton® etc.
Regional Analysis:
North America dominated the global market in 2017, with a revenue share of around 40.0%. The growth is attributed to the presence of key players such as Pfizer Inc. and Johnson & Johnson Ltd., which are engaged in commercializing these products at higher prices. In addition, high healthcare expenditure and favorable government initiatives for R&D investments are also contributing toward regional growth.
Growth Factors:
- Increasing geriatric population: The global geriatric population is expected to grow at a CAGR of around 7% from 2016 to 2020. This will lead to an increase in the demand for Dabigatran and Dabigatran Generic Drugs, as they are prescribed for the prevention of stroke and blood clotting in elderly patients.
- Rising prevalence of cardiovascular diseases: The prevalence of cardiovascular diseases is increasing at an alarming rate due to changing lifestyles and dietary habits. This is leading to an increase in the demand for anticoagulants such as Dabigatran and its generic drugs, which help prevent heart attacks and strokes.
- Technological advancements: With technological advancements, drug manufacturers are able to develop better quality generic drugs that are more affordable than their branded counterparts. This will lead to an increase in the uptake of generic drugs such as dabigatran, thereby driving market growth.
Scope Of The Report
Report Attributes
Report Details
Report Title
Dabigatran & Dabigatran Generic Drugs Market Research Report
By Type
75 mg, 110 mg, 150 mg
By Application
Online Sales, Offline Sales
By Companies
Boehringer Ingelheim, Apotex Inc, Ascend Laboratories, Teva Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Dabigatran & Dabigatran Generic Drugs Market Report Segments:
The global Dabigatran & Dabigatran Generic Drugs market is segmented on the basis of:
Types
75 mg, 110 mg, 150 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Online Sales, Offline Sales
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- Apotex Inc
- Ascend Laboratories
- Teva Pharmaceutical
Highlights of The Dabigatran & Dabigatran Generic Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 75 mg
- 110 mg
- 150 mg
- By Application:
- Online Sales
- Offline Sales
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dabigatran & Dabigatran Generic Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dabigatran is a medication used to prevent blood clots. Dabigatran generic drugs are the same as the brand name drug, but they are not patented and therefore cheaper.
Some of the major companies in the dabigatran & dabigatran generic drugs market are Boehringer Ingelheim, Apotex Inc, Ascend Laboratories, Teva Pharmaceutical.
The dabigatran & dabigatran generic drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dabigatran & Dabigatran Generic Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Dabigatran & Dabigatran Generic Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Dabigatran & Dabigatran Generic Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Dabigatran & Dabigatran Generic Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Dabigatran & Dabigatran Generic Drugs Market Size & Forecast, 2018-2028 4.5.1 Dabigatran & Dabigatran Generic Drugs Market Size and Y-o-Y Growth 4.5.2 Dabigatran & Dabigatran Generic Drugs Market Absolute $ Opportunity
Chapter 5 Global Dabigatran & Dabigatran Generic Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Type
5.2.1 75 mg
5.2.2 110 mg
5.2.3 150 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dabigatran & Dabigatran Generic Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Applications
6.2.1 Online Sales
6.2.2 Offline Sales
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dabigatran & Dabigatran Generic Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dabigatran & Dabigatran Generic Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Type
9.6.1 75 mg
9.6.2 110 mg
9.6.3 150 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Applications
9.10.1 Online Sales
9.10.2 Offline Sales
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dabigatran & Dabigatran Generic Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Type
10.6.1 75 mg
10.6.2 110 mg
10.6.3 150 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Applications
10.10.1 Online Sales
10.10.2 Offline Sales
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dabigatran & Dabigatran Generic Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Type
11.6.1 75 mg
11.6.2 110 mg
11.6.3 150 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Applications
11.10.1 Online Sales
11.10.2 Offline Sales
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dabigatran & Dabigatran Generic Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Type
12.6.1 75 mg
12.6.2 110 mg
12.6.3 150 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Applications
12.10.1 Online Sales
12.10.2 Offline Sales
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dabigatran & Dabigatran Generic Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Type
13.6.1 75 mg
13.6.2 110 mg
13.6.3 150 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dabigatran & Dabigatran Generic Drugs Market Size Forecast by Applications
13.10.1 Online Sales
13.10.2 Offline Sales
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dabigatran & Dabigatran Generic Drugs Market: Competitive Dashboard
14.2 Global Dabigatran & Dabigatran Generic Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer Ingelheim
14.3.2 Apotex Inc
14.3.3 Ascend Laboratories
14.3.4 Teva Pharmaceutical